Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 239

Cited In for PubMed (Select 20228404)

1.

Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study.

Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Gruden G, Lamacchia O, Pontiroli AE, Arosio M, Orsi E, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group.

PLoS One. 2015 May 5;10(5):e0125512. doi: 10.1371/journal.pone.0125512. eCollection 2015.

2.

Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence.

Sosale A, Saboo B, Sosale B.

Diabetes Metab Syndr Obes. 2015 Apr 15;8:189-96. doi: 10.2147/DMSO.S49592. eCollection 2015. Review.

3.

Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia.

Sun B, Xie Y, Jiang J, Wang Y, Xu X, Zhao C, Huang F.

Lipids Health Dis. 2015 Apr 14;14(1):27. doi: 10.1186/s12944-015-0032-3.

4.

Lipid-lowering therapy in older persons.

Aronow WS.

Arch Med Sci. 2015 Mar 16;11(1):43-56. doi: 10.5114/aoms.2015.48148. Epub 2015 Jan 8.

5.

Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?

Scherer DJ, Nicholls SJ.

Vasc Health Risk Manag. 2015 Mar 25;11:203-9. doi: 10.2147/VHRM.S40134. eCollection 2015. Review.

6.

Therapeutic Effects of PPAR α on Neuronal Death and Microvascular Impairment.

Moran EP, Ma JX.

PPAR Res. 2015;2015:595426. doi: 10.1155/2015/595426. Epub 2015 Jan 29. Review.

7.

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.

Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2015 May 1;36(17):1012-1022. Epub 2015 Feb 18. Review.

8.

Lipid abnormalities in kidney disease and management strategies.

Pandya V, Rao A, Chaudhary K.

World J Nephrol. 2015 Feb 6;4(1):83-91. doi: 10.5527/wjn.v4.i1.83. Review.

9.

Chapter 5: Referral to specialists and models of care.

[No authors listed]

Kidney Int Suppl (2011). 2013 Jan;3(1):112-119. No abstract available.

11.

Applications of mass spectrometry for cellular lipid analysis.

Wang C, Wang M, Han X.

Mol Biosyst. 2015 Mar;11(3):698-713. doi: 10.1039/c4mb00586d. Epub 2015 Jan 19.

PMID:
25598407
12.

Consensus statement on management of dyslipidemia in Indian subjects.

Chandra KS, Bansal M, Nair T, Iyengar SS, Gupta R, Manchanda SC, Mohanan PP, Rao VD, Manjunath CN, Sawhney JP, Sinha N, Pancholia AK, Mishra S, Kasliwal RR, Kumar S, Krishnan U, Kalra S, Misra A, Shrivastava U, Gulati S.

Indian Heart J. 2014 Dec;66 Suppl 3:S1-51. doi: 10.1016/j.ihj.2014.12.001. Epub 2014 Dec 24. No abstract available.

13.
14.
15.

Health outcomes in diabetics measured with Minnesota Community Measurement quality metrics.

Takahashi PY, St Sauver JL, Finney Rutten LJ, Jacobson RM, Jacobson DJ, McGree ME, Ebbert JO.

Diabetes Metab Syndr Obes. 2014 Dec 16;8:1-8. doi: 10.2147/DMSO.S71726. eCollection 2015.

16.

The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.

Sharina IG, Sobolevsky M, Papakyriakou A, Rukoyatkina N, Spyroulias GA, Gambaryan S, Martin E.

Br J Pharmacol. 2015 May;172(9):2316-29. doi: 10.1111/bph.13055. Epub 2015 Feb 10.

PMID:
25536881
17.

Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.

Tenenbaum A, Klempfner R, Fisman EZ.

Cardiovasc Diabetol. 2014 Dec 4;13(1):159. doi: 10.1186/s12933-014-0159-y.

18.

Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.

Ruilope L, Hanefeld M, Lincoff AM, Viberti G, Meyer-Reigner S, Mudie N, Wieczorek Kirk D, Malmberg K, Herz M.

BMC Nephrol. 2014 Nov 18;15:180. doi: 10.1186/1471-2369-15-180.

19.

Lipolysis, and not hepatic lipogenesis, is the primary modulator of triglyceride levels in streptozotocin-induced diabetic mice.

Willecke F, Scerbo D, Nagareddy P, Obunike JC, Barrett TJ, Abdillahi ML, Trent CM, Huggins LA, Fisher EA, Drosatos K, Goldberg IJ.

Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):102-10. doi: 10.1161/ATVBAHA.114.304615. Epub 2014 Nov 13.

PMID:
25395613
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk